Evidence map›Paper›PMID 27284736›Full record

ArticleBlood cancer journal2016

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.

N Nikesitch, C Tao, K Lai, M Killingsworth, S Bae, M Wang, S Harrison, T L Roberts, S C W Ling

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Research progress in proteasome inhibitor resistance to multiple myeloma.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021
    Article
  10. Article
  11. Role of Proteasomes in Inflammation.Journal of clinical medicine · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Covariance-Insured Screening.Computational statistics & data analysis · 2019
    Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

N NikesitchIngham Institute of Applied Medical Research, SWS Clinical School, Western Sydney University, Campbelltown, New South Wales, Australia.
C TaoHaematology Research Group, SWS Clinical School, University of NSW, Western Sydney University, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.
K LaiAnatomical Pathology NSWHP, Liverpool Hospital, Liverpool, New South Wales, Australia.
M KillingsworthIngham Institute of Applied Medical Research, SWS Clinical School, Western Sydney University, Campbelltown, New South Wales, Australia.
S BaeHaematology Research Group, SWS Clinical School, University of NSW, Western Sydney University, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.
M WangFlow Cytometry Core Facility, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
S HarrisonDepartment of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
T L RobertsSchool of Medicine, SWS Clinical School, University of New South Wales, Kensington, New South Wales, Australia.
S C W LingIngham Institute of Applied Medical Research, SWS Clinical School, Western Sydney University, Campbelltown, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, NeoplasmActivating Transcription Factor 6Biomarkers, PharmacologicalBiomarkers, TumorBortezomibEndoplasmic ReticulumGene Expression Regulation, NeoplasticHumansMultiple MyelomaPrognosisProteasome InhibitorsTreatment OutcomeTumor Cells, CulturedUnfolded Protein ResponseActivating Transcription Factor 6ATF6 protein, humanBiomarkers, PharmacologicalBiomarkers, TumorBortezomibProteasome Inhibitors

Identifiers

PMID27284736
PMCPMC5141355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.